Insmed completes enrollment of adult patients in phase 3 aspen study of brensocatib in bronchiectasis

—topline data remains on track to be reported in q2 of 2024— —more than 1,700 adult patients enrolled in global, registrational study of first-in-class treatment candidate— bridgewater, n.j. , march 31, 2023 /prnewswire/ -- insmed incorporated (nasdaq:insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced that adult patient enrollment is complete as of today in its pivotal aspen study of brensocatib.
INSM Ratings Summary
INSM Quant Ranking